In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice

Daniela Frasca, D. Boraschi, S. Baschieri, P. Bossu, A. Tagliabue, L. Adorini, G. Doria

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The immunorestorative capacities of human (hu) IL-1β or its synthetic fragment 163-171 (VQGEESNDK) were assessed in vivo in mice immunodepressed by aging, sublethal irradiation, or both. Subcutaneous administrtion of hu rIL-1β into immunodepressed animals immediately after carrier (horse red blood cells, HRBC) priming could restore to normal levels Th cell activity. This was measured as the ability of spleen cells from HRBC-primed mice to induce a hapten-specific antibody response in spleen cells from nonimmune mice in vitro stimulated with the hapten-carrier conjugate TNP-HRBC. In parallel, the ability of spleen cells from hu rIL-1β-treated immunodepressed animals to produce T cell growth factor activity upon in vitro mitogen stimulation was also increased significantly as compared to that of untreated mice and approached that of immunocompetent controls. The immunorestorative activity of hu rIL-1β on Th cell activity and T cell growth factor production could be mimicked by the synthetic nonapeptide 163-171 which, at the doses used, produced in most instances even greater effects than the whole protein. Although the optimal immunorestorative doses of the 163-171 peptide were several orders of magnitude higher than those of hu rIL-1β, the complete lack of IL-1-like inflammatory and toxic effects suggests that the synthetic hu IL-1β fragment may be successfully used as immunomodulating agent in the therapy of T cell immunodeficiencies.

Original languageEnglish
Pages (from-to)2651-2655
Number of pages5
JournalJournal of Immunology
Volume141
Issue number8
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Interleukin-1
T-Lymphocytes
Horses
Spleen
Haptens
Erythrocytes
Interleukin-2
Poisons
Mitogens
Human Activities
Antibody Formation
Peptides
Proteins
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Frasca, D., Boraschi, D., Baschieri, S., Bossu, P., Tagliabue, A., Adorini, L., & Doria, G. (1988). In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice. Journal of Immunology, 141(8), 2651-2655.

In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice. / Frasca, Daniela; Boraschi, D.; Baschieri, S.; Bossu, P.; Tagliabue, A.; Adorini, L.; Doria, G.

In: Journal of Immunology, Vol. 141, No. 8, 01.01.1988, p. 2651-2655.

Research output: Contribution to journalArticle

Frasca, D, Boraschi, D, Baschieri, S, Bossu, P, Tagliabue, A, Adorini, L & Doria, G 1988, 'In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice', Journal of Immunology, vol. 141, no. 8, pp. 2651-2655.
Frasca D, Boraschi D, Baschieri S, Bossu P, Tagliabue A, Adorini L et al. In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice. Journal of Immunology. 1988 Jan 1;141(8):2651-2655.
Frasca, Daniela ; Boraschi, D. ; Baschieri, S. ; Bossu, P. ; Tagliabue, A. ; Adorini, L. ; Doria, G. / In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice. In: Journal of Immunology. 1988 ; Vol. 141, No. 8. pp. 2651-2655.
@article{85bd99907f094d62b403e98fa925d57e,
title = "In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice",
abstract = "The immunorestorative capacities of human (hu) IL-1β or its synthetic fragment 163-171 (VQGEESNDK) were assessed in vivo in mice immunodepressed by aging, sublethal irradiation, or both. Subcutaneous administrtion of hu rIL-1β into immunodepressed animals immediately after carrier (horse red blood cells, HRBC) priming could restore to normal levels Th cell activity. This was measured as the ability of spleen cells from HRBC-primed mice to induce a hapten-specific antibody response in spleen cells from nonimmune mice in vitro stimulated with the hapten-carrier conjugate TNP-HRBC. In parallel, the ability of spleen cells from hu rIL-1β-treated immunodepressed animals to produce T cell growth factor activity upon in vitro mitogen stimulation was also increased significantly as compared to that of untreated mice and approached that of immunocompetent controls. The immunorestorative activity of hu rIL-1β on Th cell activity and T cell growth factor production could be mimicked by the synthetic nonapeptide 163-171 which, at the doses used, produced in most instances even greater effects than the whole protein. Although the optimal immunorestorative doses of the 163-171 peptide were several orders of magnitude higher than those of hu rIL-1β, the complete lack of IL-1-like inflammatory and toxic effects suggests that the synthetic hu IL-1β fragment may be successfully used as immunomodulating agent in the therapy of T cell immunodeficiencies.",
author = "Daniela Frasca and D. Boraschi and S. Baschieri and P. Bossu and A. Tagliabue and L. Adorini and G. Doria",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "141",
pages = "2651--2655",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - In vivo restoration of T cell functions by human IL-1β or its 163-171 nonapeptide in immunodepressed mice

AU - Frasca, Daniela

AU - Boraschi, D.

AU - Baschieri, S.

AU - Bossu, P.

AU - Tagliabue, A.

AU - Adorini, L.

AU - Doria, G.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The immunorestorative capacities of human (hu) IL-1β or its synthetic fragment 163-171 (VQGEESNDK) were assessed in vivo in mice immunodepressed by aging, sublethal irradiation, or both. Subcutaneous administrtion of hu rIL-1β into immunodepressed animals immediately after carrier (horse red blood cells, HRBC) priming could restore to normal levels Th cell activity. This was measured as the ability of spleen cells from HRBC-primed mice to induce a hapten-specific antibody response in spleen cells from nonimmune mice in vitro stimulated with the hapten-carrier conjugate TNP-HRBC. In parallel, the ability of spleen cells from hu rIL-1β-treated immunodepressed animals to produce T cell growth factor activity upon in vitro mitogen stimulation was also increased significantly as compared to that of untreated mice and approached that of immunocompetent controls. The immunorestorative activity of hu rIL-1β on Th cell activity and T cell growth factor production could be mimicked by the synthetic nonapeptide 163-171 which, at the doses used, produced in most instances even greater effects than the whole protein. Although the optimal immunorestorative doses of the 163-171 peptide were several orders of magnitude higher than those of hu rIL-1β, the complete lack of IL-1-like inflammatory and toxic effects suggests that the synthetic hu IL-1β fragment may be successfully used as immunomodulating agent in the therapy of T cell immunodeficiencies.

AB - The immunorestorative capacities of human (hu) IL-1β or its synthetic fragment 163-171 (VQGEESNDK) were assessed in vivo in mice immunodepressed by aging, sublethal irradiation, or both. Subcutaneous administrtion of hu rIL-1β into immunodepressed animals immediately after carrier (horse red blood cells, HRBC) priming could restore to normal levels Th cell activity. This was measured as the ability of spleen cells from HRBC-primed mice to induce a hapten-specific antibody response in spleen cells from nonimmune mice in vitro stimulated with the hapten-carrier conjugate TNP-HRBC. In parallel, the ability of spleen cells from hu rIL-1β-treated immunodepressed animals to produce T cell growth factor activity upon in vitro mitogen stimulation was also increased significantly as compared to that of untreated mice and approached that of immunocompetent controls. The immunorestorative activity of hu rIL-1β on Th cell activity and T cell growth factor production could be mimicked by the synthetic nonapeptide 163-171 which, at the doses used, produced in most instances even greater effects than the whole protein. Although the optimal immunorestorative doses of the 163-171 peptide were several orders of magnitude higher than those of hu rIL-1β, the complete lack of IL-1-like inflammatory and toxic effects suggests that the synthetic hu IL-1β fragment may be successfully used as immunomodulating agent in the therapy of T cell immunodeficiencies.

UR - http://www.scopus.com/inward/record.url?scp=0023790536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023790536&partnerID=8YFLogxK

M3 - Article

C2 - 2971727

AN - SCOPUS:0023790536

VL - 141

SP - 2651

EP - 2655

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -